Related Experiment Video
Updated: Oct 30, 2025
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.3K
Immune thrombocytopenia: options and new perspectives
Santino Caserta1, Anna Maria Zaccuri, Vanessa Innao
1Division of Hematology, Department of Human Pathology in Adulthood and Childhood 'Gaetano Barresi', University of Messina, Messina, Italy.
Summary
New treatments for immune thrombocytopenia (ITP) focus on improving platelet production and survival, aiming for better patient quality of life with fewer side effects. Research continues to evaluate long-term efficacy of these novel therapies.
Area of Science:
- Hematology
- Autoimmunology
- Pharmacology
Background:
- Immune thrombocytopenia (ITP) is an autoimmune disorder causing excessive platelet destruction by autoantibodies and impaired platelet production.
- Current ITP management includes established therapies, but novel approaches are emerging.
Purpose of the Study:
- To review recent advancements in ITP treatment, focusing on new drugs, their mechanisms, and dosages.
- To highlight the association between COVID-19 and ITP.
- To emphasize the need for treatments that enhance platelet production and survival while improving patient quality of life and minimizing adverse events.
Main Methods:
- Literature review of recent scientific publications on immune thrombocytopenia treatments.
- Analysis of mechanisms of action and posology of new therapeutic agents.
- Inclusion of data on COVID-19 related ITP.
Main Results:
- New drugs offer targeted mechanisms for ITP treatment, addressing both platelet destruction and production.
- The link between COVID-19 and ITP is recognized as a significant clinical observation.
- Ideal ITP therapies aim for comprehensive improvement in platelet counts, patient well-being, and safety.
Conclusions:
- Novel pharmacological agents represent a significant step forward in managing immune thrombocytopenia.
- Further research is essential to fully elucidate the long-term effectiveness and safety profiles of these new ITP treatments.
- Optimizing ITP care requires a holistic approach balancing efficacy, safety, and patient quality of life.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
72
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
72
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
781
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
781
01:29Inflammatory Bowel Disease IV: Pharmacological Management
250
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
250
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
78
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
78